Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Trial Timeline
Feb 1, 2016 → Jul 25, 2016
NCT ID
NCT02633527About Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 is a phase 2 stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02633527. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02633527 | Phase 2 | Completed |
Competing Products
18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| ABT-089 + atomoxetine + placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-089 | AbbVie | Phase 2 | 52 |
| ABT-089 + placebo | AbbVie | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| IR Viloxazine + Placebo | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| 100mg SPN-812 + Placebo | Supernus Pharmaceuticals | Approved | 80 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| TD-9855 + TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |